Frontiers in Oncology | |
Applications of large language models in cancer care: current evidence and future perspectives | |
Oncology | |
Charalampos S. Floudas1  Dara Bracken-Clarke1  James L. Gulley1  Fatima Karzai2  Giovanni Maria Iannantuono3  Mario Roselli4  | |
[1] Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States;Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States;Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States;Medical Oncology Unit, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy;Medical Oncology Unit, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy; | |
关键词: artificial intelligence; large language models; chatbot; cancer care; ChatGPT; | |
DOI : 10.3389/fonc.2023.1268915 | |
received in 2023-07-28, accepted in 2023-08-21, 发布年份 2023 | |
来源: Frontiers | |
【 摘 要 】
The development of large language models (LLMs) is a recent success in the field of generative artificial intelligence (AI). They are computer models able to perform a wide range of natural language processing tasks, including content generation, question answering, or language translation. In recent months, a growing number of studies aimed to assess their potential applications in the field of medicine, including cancer care. In this mini review, we described the present published evidence for using LLMs in oncology. All the available studies assessed ChatGPT, an advanced language model developed by OpenAI, alone or compared to other LLMs, such as Google Bard, Chatsonic, and Perplexity. Although ChatGPT could provide adequate information on the screening or the management of specific solid tumors, it also demonstrated a significant error rate and a tendency toward providing obsolete data. Therefore, an accurate, expert-driven verification process remains mandatory to avoid the potential for misinformation and incorrect evidence. Overall, although this new generative AI-based technology has the potential to revolutionize the field of medicine, including that of cancer care, it will be necessary to develop rules to guide the application of these tools to maximize benefits and minimize risks.
【 授权许可】
Unknown
Copyright © 2023 Iannantuono, Bracken-Clarke, Floudas, Roselli, Gulley and Karzai
【 预 览 】
Files | Size | Format | View |
---|---|---|---|
RO202310104428945ZK.pdf | 567KB | download |